Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

January 31, 2028

Conditions
Small Cell Lung Cancer, Limited StageHyperfractionated Accelerated RadiotherapySimultaneous Radiotherapy and Chemotherapy
Interventions
DRUG

Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy

"Chemotherapy:~Etoposide will be administered intravenously at a dose of 100 mg/m² on days 1 to 3 of each cycle. Cisplatin will be given at a dose of 75 mg/m² on day 1 of each cycle. The treatment will be repeated every 3 weeks for a total of 4 cycles.~Concurrent Radiotherapy:~Chest radiotherapy will be initiated concurrently with the first 3 cycles of chemotherapy. The total dose of radiotherapy will be 54 Gy, delivered in 30 fractions, with 2 fractions per day.~Prophylactic Cranial Irradiation (PCI):~For patients who achieve a partial response (PR) or complete response (CR) after chemoradiotherapy, PCI will be administered 3 to 4 weeks after the completion of chemoradiotherapy. The dose for PCI will be 25 Gy in 10 fractions.~Adebrelimab Maintenance Therapy:~Following PCI, patients will receive maintenance therapy with Adebrelimab. The dose will be 1200 mg administered intravenously on day 1 of each cycle. The treatment will be repeated every 3 weeks until disease progression, death"

Trial Locations (1)

100142

Peking University Cancer Hospital and Institute, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER